Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Benjamin Lacas; Alexandra Carmel; C. Landais; Stuart J. Wong; Lisa Licitra; Jeffrey Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E.W. Cohen; Cai Grau; Gregory T. Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean‐Jacques Mazeron; Lai‐ping Zhong; W. Dobrowsky; Pirus Ghadjar; C. Fallai; Branko Zakotnik; Atul Sharma; René‐Jean Bensadoun; Maria Grazia Ruo Redda; S. Racadot; George Fountzilas; David M. Brizel; P Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju‐Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean‐Pierre Pignon; David J. Adelstein; M. Alfonsi; Y. Belkacemi; Voichita Bar‐Ad; J. Bernier; Åse Bratland; G. Calais; Brittany Campbell; Jimmy J. Caudell; Sylvie Chabaud; Emmanuel Chamorey; Devendra Chaukar; Kwang Nam Choi; Olivier Choussy; Laurence Collette; Judith Cruz; Carla Dani; Etienne Dauzier; Arlene A. Forastiere; P. Garaud; V. Grégoire; A. Hackshaw; E. Haddad; Bruce G. Haffty; Aaron R. Hansen; Stefanie Hayoz; Jean-Claude Horiot; Branislav Jeremić; Theodore Karrison; Johannes A. Langendijk; M. Lapeyre; Éric Lartigau; Traci Leong; Quynh‐Thu Le; Patricia Lee; Freddi Lewin; Aihua Lin; Alberto Lopes; Samir Mehta; James Moon; Elizabeth Moyal; Bob‐Valéry Occéan; P. Olmi; Roberto Orecchia; Brian O’Sullivan; Jens Overgaard; Claire Petit; Harvey Quon; Giuseppe Sanguineti; Tuvana Satar; John Simes; Christian Simon; Clément Sire; S. Staar; C. Stromberger; P. Strojan; Stéphane Temam; David Thomson; A. Timochenko; Valter Torri; Vassilikì Tseroni; Jan B. Vermorken

doi:10.1016/j.radonc.2021.01.013

January 27, 2021Radiotherapy and OncologyOpen Access

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

View Full Paper

Ask AI

Bookmark

Share

Key Points

To update the MACH-NC collaborative meta-analysis evaluating the clinical efficacy and benefit of adding chemotherapy to primary treatment in non-metastatic head and neck cancer.
Conducted an updated meta-analysis of individual patient data across 107 randomized controlled trials.
Included 19,805 patients diagnosed with non-metastatic head and neck cancer.
Evaluated the specific therapeutic effect of adding concomitant chemotherapy.
Confirmed a statistically significant survival benefit with the addition of concomitant chemotherapy.
Demonstrated the clinical superiority of concomitant chemotherapy compared to alternative treatment timing and regimens.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Meta-analysis reveals superior outcomes with concomitant chemotherapy in non-metastatic head and neck cancer, indicating clear clinical benefit.

Abstract

The update of MACH-NC confirms the benefit and superiority of the addition of concomitant CT for non-metastatic head and neck cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lacas et al. (2021) studied this question.

synapsesocial.com/papers/69dac4f478a3e0e288684510 https://doi.org/10.1016/j.radonc.2021.01.013

View Full Paper

Ask AI

Bookmark

Share

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading